Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin

Infection

Volumn 42, Issue 1, 2014, Pages 175-177

  Lutz, P ^a   Parcina, M ^a   Bekeredjian Ding, I ^a   Hoerauf, A ^a   Strassburg, C P ^a   Spengler, U ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cirrhosis; Liver; Non absorbable antibiotic; Pet; Prophylaxis

Indexed keywords

BILIRUBIN; CEFTRIAXONE; CIPROFLOXACIN; CREATININE; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER FUNCTION; LONG TERM CARE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; PARACENTESIS; PASTEURELLA MULTOCIDA; PORTAL VEIN THROMBOSIS;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFTRIAXONE; FEMALE; HUMANS; LIVER CIRRHOSIS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PASTEURELLA INFECTIONS; PASTEURELLA MULTOCIDA; PERITONITIS; RIFAMYCINS; TREATMENT OUTCOME;

EID: 84898543215     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0449-4     Document Type: Article

References (20)

1. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73:13-27.
2. Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19:352-6.
3. Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, Kwon CI, Ko KH, Hwang SG, Park PW, Hong SP. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452-6.
4. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122-8.
5. Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, Hazratjee N, Smith T, Zein NN. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46:709-15.
6. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450-5.
7. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012;61:297-310.
8. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-81.
9. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a metaanalysis. World J Gastroenterol. 2012;18:767-77.
10. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417.
11. Hubbert WT, Rosen MN. Pasteurella multocida infections. II. Pasteurella multocida infection in man unrelated to animal bite. Am J Public Health Nations Health. 1970;60:1109-17.
12. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551-61.
13. Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T. Emergence of spontaneous bacterial peritonitis due to enterococci-risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther. 2012;35:1199-208.
14. Tamaskar I, Ravakhah K. Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J. 2004;97:1113-5. (Pubitemid 39518707)
15. Sol PM, van de Kar NC, Schreuder MF. Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: a case report and review of the literature. Int J Hyg Environ Health. 2013;216:211-3.
16. Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol. 2011;49:4319-21.
17. Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811-7.
18. Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, Salzer HJ, Krause R. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34-8.
19. Avril JL, Donnio PY, Pouedras P. Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol. 1990;28:1438-40. (Pubitemid 20194447)
20. Siahanidou T, Gika G, Skiathitou AV, Oikonomopoulos T, Alexandrou-Athanassoulis H, Koutouzis EI, Syriopoulou VP. Pasteurella multocida infection in a neonate: evidence for a human-to-human horizontal transmission. Pediatr Infect Dis J. 2012;31:536-7.